About ImmunoScape

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. Our proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple solid tumors. We currently have multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.

Leadership

Choon-Peng Ng, MBA

Choon-Peng Ng, MBA

Chief Executive Officer

Alessandra Nardin, DVM

Alessandra Nardin, DVM

Chief Operating Officer

Romi Chandiramani, CA

Romi Chandiramani, CA

Chief Financial Officer

Mathew Cobbett

Mathew Cobbett, MBA

Vice President, North America

Michael Fehlings, PhD

Michael Fehlings, PhD

Vice President, Operations and Development

Dan MacLeod

Dan MacLeod, PhD

Vice President, Discovery

Choon-Peng Ng, MBA

Choon-Peng Ng, MBA

Chief Executive Officer

Alessandra Nardin, DVM

Alessandra Nardin, DVM

Chief Operating Officer

Naonori Kurokawa

Director,
UTEC

David Michael

MANAGING PARTNER,
Anzu Partners

Arian Woolfson

Adrian Woolfson, PhD

Cofounder, President, and Executive Chairman of Replay

Evan Newell, PhD

Co-Founder/Advisor, ImmunoScape;
Associate Professor, Fred Hutchinson Cancer Research Center

Dr. Philip Greenberg

Philip Greenberg, M.D.

Professor, University
of Washington;
Head of Program (Immunology), Fred Hutchinson Cancer Research Center

Dr. Paul Thomas

Paul Thomas, PhD

Member, St. Jude
Children's Research Hospital in Memphis, TN

Dr. Patrick Reeves

Patrick Reeves, PhD

Team Leader,
Massachusetts General Hospital

Rachel Humphrey, M.D.

Chief Executive Officer, new venture

Arian Woolfson

Adrian Woolfson, PhD

Cofounder, President, and Executive Chairman of Replay

EDBi logo
Top